Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Izeltabart tapatansine - Immunogen

Next Previous
Drug Profile

Izeltabart tapatansine - Immunogen

Alternative Names: Anti-ADAM9 antibody-drug conjugate -ImmunoGen; IMGC-936

Latest Information Update: 17 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen; MacroGenics
  • Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer; Triple negative breast cancer

Most Recent Events

  • 23 Oct 2024 Efficacy, pharmacokinetics and adverse events data from a phase I/II trial in Solid tumours presented at the 36th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (EORTC-NCI-AACR Symposium-2024)
  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 31 Dec 2023 Discontinued - Phase-I/II for Colorectal cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top